Adicet Bio, Inc.
200 Constitution Drive
About Adicet Bio, Inc.
Adicet Bio, Inc. is a well-funded, privately held, pre-clinical stage biotechnology company that is engaged in the development of cutting-edge immunotherapies that have the potential to profoundly transform the treatment of cancer and other diseases and we are growing!
ABOUT ADICET BIO
Adicet is developing the next generation immunotherapies by generating a pipeline of allogeneic gamma delta T cell products engineering with CAR or TCR. In addition, Adicet's immune cell platform is complemented by its ability to identify and validate novel disease specific peptide-MHC targets and generates T cell receptor-like antibodies directed against these disease-specific peptide MHC complexes. Adicet Bio was founded in late 2015 and closed a Series A financing of $51M in Jan 2016. This financing was led by OrbiMed and included Novartis Venture Funds and Pontifax. In August 2016, Regeneron and Adicet Bio announced a strategic collaboration to discover and develop next-generation engineered immune-cell therapeutics, for which Adicet received a $25M upfront payment. In September 2016, Adicet Bio was recognized and named by FierceBiotech to its “Fierce 15” Biotech Companies of 2016.
7 articles with Adicet Bio, Inc.
Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits
Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that Aya Jakobovits, Ph.D., Founder of Adicet Bio, has retired from her position as President and Chief Executive Officer.
After Bagging $51 Million in Early 2016, Bay Area's Adicet Bio Inks a Five-Year R&D Deal with Regeneron
The Bay Area's Secretive Adicet Bio Raises $51 Million and Buys Israel-based Applied Immune Technologies